3D InSight™ Human Liver Microtissues
Discover the 3D InSight™ Human Liver Microtissues: the gold standard for Hepatotoxic screening. Pharma-validated co-culture models offer 2x higher DILI prediction sensitivity than 2D hepatocytes. Features pooled PHH from male/female donors co-cultured with Kupffer cells and LECs, 28-day viability, in 96-well format. Includes 50mL 3D InSight™ Liver Maintenance Medium. Check the bi-weekly production schedule online.
The supplier does not provide quotations for this product through SelectScience. You can search for similar products in our Product Directory.
By combining multi-donor diversity with structural and functional robustness, our models are ideal for drug safety and efficacy testing as well as the study of healthy and diseased liver function.
Microtissues are shipped in our InFloat™ Shipping System which includes our Akura™ 96 Plates (one microtissue per well), with 3D InSight™ Human Liver Microtissue Maintenance Medium - AF/TOX, our recommended medium for routine culture and maintenance of liver microtissues.
- Reflect the average response of a population with a model incorporating hepatocytes from 5 male and 5 female donors.
- Achieve the highest biological relevance in an in vitro model with primary hepatocyte, Kupffer cell, and liver endothelial cell (LEC) co-cultures.
- Test long-term effects of drug exposure in an organotypic, functional liver model.
- Highly reproducible and robust liquid handling in InSphero’s patented Akura™ 96 Plates (engineered to protect microtissues from accidental aspiration).
- Complete turnkey solutions offer lower cost-of-ownership than in-house production.
You can also request 3D InSight™ Human Liver Microtissue Medium - TOX, which we recommend for Hepatotoxicity testing applications.
_Shipping date to be confirmed by our customer service team after checkout
Innovation in 3D in vitro oncology
Insphero offers advanced 3D in vitro technology for immuno-oncology screening, and presents the 3D InSight™ Tumor Microtissue in the assessment of Antibody-Drug Conjugates (ADCs) efficacy and penetration depth. InSphero further highlights the product's capabilities including the evaluation of various therapeutic modalities, such as antibody-based therapeutics, with confidence, covering mechanisms of action, immune cell engagement, off-target effects, and more.
Human 3D InSight tumor spheroids
Tumor spheroids are three-dimensional cellular models that mimic the complex microenvironment of tumors, facilitating advanced drug screening and research in oncology. InSphero introduces 3D InSight™ Tumor Spheroids for advanced immuno-oncology (IO) drug discovery. The spheroids offer high physiological relevance, scalability, and reliability, effectively modeling the complex tumor microenvironment (TME). With a wide array of tumor cell lines, including cancer-associated fibroblasts (CAFs) and immune cells, these spheroids mimic tumor heterogeneity and microenvironment interactions.
3D InSight tumor spheroids
3D tumor spheroids comprise of various tumor cell lines and components of the tumor microenvironment, therefore accurate testing of anti-cancer therapies while maintaining consistency and reproducibility can prove challenging. InSphero highlights human 3D InSight™ Tumor Spheroids, offering a blend of physiological relevance, scalability, and reliability for oncology therapeutic testing. With the flexibility to accommodate different throughput needs and the capability to mimic tumor heterogeneity, they provide a robust platform for advanced drug discovery in oncology.
Efficacy of cell reprogramming using 3D spheroid model
Cancer ranks as the second leading cause of death globally, with immunotherapy offering promise but facing limitations in clinical success. Recent studies reveal that overexpression of PU.1, IRF8, and BATF3 transcription factors induces the transformation of tumor cells into antigen-presenting dendritic cells, potentially enhancing anticancer immunity. However, existing testing platforms struggle to replicate the intricate cell interactions necessary to validate this approach. InSphero presents the 3D InSight™ Oncology Platform as a tool to assess the efficacy and immune-stimulatory effects of tumor-dendritic cell reprogramming.
Explore the InSphero MASH CALL initiative
In this application note, explore the InSphero MASH CALL initiative, a fast and cost-effective identification of drug candidates in MASH (Metabolic Dysfunction-associated Steatohepatitis, renamed from NASH). Furthermore, discover how the 3D InSight™ Liver Microtissue MASH model is a robust, reproducible and translational model that can recapitulate human hallmarks of MASH predictive of clinical candidates.
